Form 4: Eli Lilly Executive Anne E. White Reports Acquisition of Common Stock and Restricted Stock Units

EVP & President of Lilly Neuroscience, Anne E. White, reports acquiring common stock and restricted stock units of Eli Lilly & Co.

Summary

• On February 10, 2025, Anne E. White, EVP & President of Lilly Neuroscience at Eli Lilly & Co, reported a transaction.
• White acquired 6,828.871 shares of common stock at a price of $868.88 per share.
• Following the transaction, White directly owns 74,209.769 shares of common stock.
• White also acquired 3,572 restricted stock units, each representing a contingent right to receive one share of Eli Lilly and Company common stock.
• These restricted stock units are exercisable from February 1, 2026, and expire on February 1, 2026.
• After the transaction, White directly owns 3,572 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive. The acquisition of shares could be seen as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of shares by a high-ranking executive could be interpreted as a positive signal about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's future performance.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates